Barclays PLC Puma Biotechnology, Inc. Call Options Transaction History

Barclays PLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2019 Nov 14, 2019	BUY	$8.75 - $12.85 $2,625 - $3,855	300 Added 25.0%	1,500 $16,000
Q4 2018 Feb 14, 2019	SELL	$20.07 - $46.7 $32,112 - $74,720	-1,600 Reduced 57.14%	1,200 $24,000
Q3 2018 Nov 14, 2018	SELL	$41.2 - $59.85 $2.36 Million - $3.42 Million	-57,200 Reduced 95.33%	2,800 $128,000
Q2 2018 Aug 14, 2018	BUY	$48.3 - $68.25 $2.84 Million - $4.02 Million	58,900 Added 5354.55%	60,000 $3.55 Million
Q1 2018 May 15, 2018	SELL	$59.7 - $99.25 $1.5 Million - $2.49 Million	-25,100 Reduced 95.8%	1,100 $75,000
Q4 2017 Feb 14, 2018	BUY	$93.85 - $132.45 $2.44 Million - $3.44 Million	26,000 Added 13000.0%	26,200 $2.59 Million
Q3 2017 Nov 14, 2017	BUY	$72.0 - $119.75 $14,400 - $23,950	200	200 $24,000

100

29M

50.6K

16.3K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $137M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.